The X-PECT phase III clinical trial has finished recruiting over 430 patients, evaluating perifosine treatment for patients with advanced colorectal cancer who have exhausted standard treatments.
The trial compares the effectiveness of adding perifosine to Xeloda® (capecitabine).
Led by Johanna Bendell, M.D., from the Sarah Cannon Research Institute in Nashville, TN, the trial is being conducted at 65 sites in the United States. Read the rest of this entry »
The FDA issued a shortage update for leucovorin on July 21, 2011.
While leucovorin remains in shortage from all three US manufacturers, the FDA is temporarily allowing Teva Pharmaceuticals to import calcium folinate solution for injection from Europe. The imported solution is the same strength as powdered leucovorin calcium for injection once water is added to the US product.
In a Dear Healthcare Professional letter, Teva provides a chart comparing the two products and tells doctors and pharmacists that currently Teva is the only organization with regulatory discretion to import and distribute calcium folinate solution. Read the rest of this entry »
A phase II clinical trial in Japan showed improved survival time for TAS-102 when compared to a placebo in patients whose cancer had progressed on standard treatments.
Median survival was 9 months for patients who received oral TAS-102 compared to 6.6 months on placebo.
Taiho Pharmaceutical says that they are proceeding with a larger Phase III trial. Read the rest of this entry »
More evidence has emerged that strong laxatives before bowel surgery don’t reduce complications after surgery, nor do they improve survival.
Traditionally, doctors prescribed laxatives to completely remove all feces from the colon before surgery, a process known as mechanical bowel preparation.
However, a study in Scotland that looked at 1,730 colon cancer surgeries performed between 2000 and 2005 found no differences in surgical complications 30 days after surgery whether patients got mechanical bowel preps or not. In addition, during 3 to 5 years of follow-up there was no difference in survival.
Screening all new colon and rectal cancer tumors for markers that might indicate Lynch syndrome not only saves future lives, it is cost effective according to a new study.
In order for tumor screening to be cost-effective, not only should new tumors be tested, but family members need to follow through with genetic testing after a new Lynch mutation is found. Finally people with Lynch syndrome mutations need to follow surveillance guidelines to prevent cancer or find it early,
Testing both tumors and at least three to four family members could cost as little of $36,000 per life year saved — well within the value of preventive health strategies. Read the rest of this entry »
Together we are Strong
